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Abstract
Histone posttranslational modifications (PTMs) play a pivotal role in regulating the dynamics and
function of chromatin. Supported by an increasing body of literature, histone PTMs such as
methylation and acetylation function together in the context of a “histone code,” which is read, or
interpreted, by effector proteins that then drive a functional output in chromatin (e.g., gene
transcription). A growing number of domains that interact with histones and/or their PTMs have
been identified. While significant advances have been made in our understanding of how these
domains interact with histones, a wide number of putative histone-binding motifs have yet to be
characterized, and undoubtedly, novel domains will continue to be discovered. In this chapter, we
provide a detailed method for the construction of combinatorially modified histone peptides,
microarray fabrication using these peptides, and methods to characterize the interaction of effector
proteins, antibodies, and the substrate specificity of histone-modifying enzymes. We discuss these
methods in the context of other available technologies and provide a user-friendly approach to
enable the exploration of histone–protein–enzyme interactions and function.
1. INTRODUCTION
More than 15 years ago, Allis and Schreiber independently identified the molecular link
between histone posttranslational modifications (PTMs) and transcriptional regulation
(Brownell et al., 1996; Taunton, Hassig, & Schreiber, 1996). Since then, a significant effort
has been placed on the identification and biological characterization of histone PTMs, which
function in DNA-templated processes such as transcription, recombination, and DNA repair
(Kouzarides, 2007). The N- and C-terminal “tails” of the four core histone proteins are rich
in amino acids that are known sites of PTM (Fig. 6.1). These PTMs include, but are not
limited to, methylation, acetylation, and ubiquitination of lysine, and phosphorylation of
serine and threonine. How the myriad of known histone PTMs function has remained a
fundamental question in modern biology.
It is thought that histone PTMs function to regulate the diverse activities associated with
chromatin (Gardner, Allis, & Strahl, 2011; Kornberg & Lorch, 1999; Kouzarides, 2007).
The “histone code” hypothesis, formally introduced just over a decade ago, suggests that
histone PTMs function in a combinatorial fashion to regulate chromatin structure and
function (Jenuwein & Allis, 2001; Strahl & Allis, 2000). We now know that histone PTMs
such as lysine acetylation can directly alter the physical structure of chromatin by charge
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neutralization (Shogren-Knaak et al., 2006), and PTMs can also serve as binding sites for
effector proteins that contain one or more well-characterized protein folds (Taverna, Li,
Ruthenburg, Allis, & Patel, 2007). For example, methyllysine can be recognized by motifs
like chromodomains and plant homeodomains (PHD), while acetyllysine can be recognized
by bromodomains. Increasing evidence is emerging to support the “histone code”
hypothesis, in the context of both effector protein binding and antibody recognition (Bock et
al., 2011; Fuchs & Strahl, 2011; Garske et al., 2010), and more recently on the multivalent
engagement of effector proteins with chromatin through linked recognition domains (Allis &
Muir, 2011; Ruthenburg, Li, Patel, & Allis, 2007). A notable example of the latter is the
recent finding that the paired bromodomain and PHD finger of the BPTF subunit of the
NURF chromatin-remodeling complex simultaneously engage nucleosomes bearing H4
lysine 16 acetylation (H4K16ac) and H3 lysine 4 trimethylation (H3K4me3), respectively
(Ruthenburg et al., 2011).
In the past few years, a number of successful strategies have been used to discover and
characterize proteins (and their domains) that recognize histones and histone PTMs. These
range from high-throughput batch screening of purified proteins using large peptide libraries
on beads (Garske et al., 2010), discovery-based approaches utilizing stable isotope labeling
with amino acids in culture (SILAC) combined with peptide and/or nucleosomal pull-downs
(Vermeulen et al., 2011), and a number of peptide microarray-based approaches utilizing
purified recombinant proteins (Bock et al., 2011; Bua et al., 2009; Nady, Min, Kareta,
Chedin, & Arrowsmith, 2008). Bead-based approaches have significant advantages in the
large library size that can be created but require labor-intensive screening to identify “hits.”
SILAC-based approaches offer tremendous potential to identify novel histone-interacting
proteins and protein complexes. However, they do not report on the domain, or protein from
within a complex, that binds to the peptide or nucleosome used in the pull-down. Peptide
microarrays provide an extremely rapid and robust method for measuring binding to a large
number of peptide substrates, although the development of the peptide library itself may be
time intensive. While each of the different approaches to identify and characterize histone-
interacting proteins have their advantages and disadvantages, it is clear that these approaches
are valuable ways to characterize histone interactions and are fundamental to advancing the
chromatin field.
Here, we describe a microarray approach using high-purity biotinylated peptides spotted
onto streptavidin-coated glass slides. We describe the peptide synthesis and the microarray
fabrication as well as the methodology for using these microarrays to probe the binding of
not only histone-binding proteins but also PTM-specific antibodies and histone-modifying
enzymes.
2. HISTONE PEPTIDE LIBRARY
The generation of any peptide microarray begins at the number and type of peptides one
needs for a given project. For example, a large number of biotinylated histone peptides
bearing one to several histone PTMs are now commercially available; thus production of
high-density peptide microarrays is feasible without the need for peptide synthesis. For some
projects, however, certain histone PTMs (or combinations thereof) may not be available.
While custom-made peptides can be purchased from a variety of commercial vendors,
commercial synthesis of peptides can be very expensive and the quality of such peptides is
often variable. We recommend that the quality of any purchased peptide be verified
independently by mass spectrometry and analytical reversed-phase high-performance liquid
chromatography (RP-HPLC) (see Section 2.3). Alternatively, performing peptide synthesis
de novo, using easily obtainable peptide synthesis equipment and reagents, can be a cost-
saving measure to produce significant quantities of high-quality peptides when the needed
Rothbart et al. Page 2













peptides are not readily available or very expensive. Moreover, the synthesized peptides can
be used for biophysical approaches like isothermal titration calorimetry (ITC) or surface
plasmon resonance (SPR). Below, we summarize our recent experience creating a focused
library of biotinylated histone peptides containing multiple PTMs (Fuchs, Krajewski, Baker,
Miller, & Strahl, 2011). In this study, a 110-peptide library was generated within a few
months using a PS3 peptide synthesizer (Protein Technologies, Inc.), which requires little
training and is easy to use. Subsequently, this library was considerably expanded using the
more sophisticated Symphony multiple peptide synthesizer (Protein Technologies, Inc.).
A variety of books and publications on the general procedures of
fluorenylmethyloxycarbonyl (Fmoc)-based solid phase peptide synthesis (SPPS) have
already been published (Abelson, Simon, & Fields, 1997; Amblard, Fehrentz, Martinez, &
Subra, 2006; Chan & White, 2000; Coin, Beyermann, & Bienert, 2007; Howl, 2005).
Therefore, this chapter focuses primarily on the synthesis of biotinylated histone peptides
containing one or more PTMs. The design strategies are highlighted further below.
2.1. Peptide library design
The biological question one is trying to answer dictates the design of the peptide library. For
example, in order to identify a region of a histone or a histone PTM that is important for the
association of a poorly characterized effector protein, one would likely want to generate a
simple histone peptide library containing only unmodified peptides and histone peptides
carrying one PTM. However, if an associated PTM for an effector protein is already known,
one would want to develop an expanded peptide library that includes additional
modifications surrounding the site of modification the effector protein binds to (in order to
determine how neighboring PTMs influence the binding of the effector protein that is under
investigation). Below we expand upon some of the important factors that should be
considered when designing a histone peptide library for binding or enzymatic studies.
2.1.1 Position of the biotin tag—Adding D-biotin at either the N- or C-terminus of the
peptide is required for immobilization onto streptavidin-coated slides. For peptides
representing the N-terminus of a histone tail, a biotin tag is incorporated at the C-terminus of
the sequence. For peptides representing the C-terminus of a histone tail, the biotin tag is
incorporated at N-terminus of the sequence. This placement is important, as it mimics the
manner in which the histone “tails” are displayed from the nucleosome core. For peptides
representing regions within the core histone fold, we typically incorporate the biotin tag at
the C-terminus of the sequence and acetylate the N-terminal amine group (to mimic a more
natural N-terminal amide bond). If a functionally important region of a histone in the peptide
sequence is in close proximity to the biotinylated terminus of the peptide, a short
polyethylene glycol (PEG) linker (~20 Å long, see Fig. 6.2A) is added to separate the
histone peptide sequence away from the D-biotin tag and the streptavidin surface.
2.1.2 Length of the peptide sequence—Peptide synthesis on a PS3 (or similar peptide
synthesizer) followed by RP-HPLC purification and analysis of each peptide (MS and
analytical RP-HPLC) comfortably allows for the synthesis of peptides surpassing 20 amino
acids in length. This is considerably longer than what is achievable by other peptide
synthesis technologies, such as synthetic peptide microarrays on membrane support (SPOT
synthesis), typically between 10 and 15 amino acids in length (Hilpert, Winkler & Hancock,
2007; Nady et al., 2008). We find that histone peptides containing 20–25 residues can be
easily synthesized and purified with ≥90% purity by RP-HPLC. Synthesis of longer
sequences (30–40 residues) is also possible but is more time consuming and usually
complicates peptide purification. In general, histone tail sequences are usually water soluble,
so longer peptides are easier to generate and purify. However, for peptides representing
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internal sequences, such as the histone fold region, synthesizing shorter peptides is
recommended due to potential problems with peptide solubility.
We prefer to synthesize the longest histone tail peptides possible for several reasons. (1)
Longer histone peptides allow us to experimentally test the importance of a greater number
of PTM combinations. (2) There is experimental evidence that long-range interactions are
biologically meaningful for the binding of certain histone-modifying enzymes and/or
effector proteins. For example, the histone demethylase JMJD2A binds H3K4me3 and
demethylates lysines 9 and 36 on histone H3 (Huang, Fang, Bedford, Zhang, & Xu, 2006;
Klose et al., 2006; Whetstine et al., 2006). (3) Having peptide-based libraries with longer
sequences carries a considerable advantage in downstream projects and applications. For
several effector proteins, we have now observed much higher affinities by ITC and
fluorescence polarization (FP) using longer peptides than the values published using shorter
peptide sequences carrying the same PTMs (Rothbart et al., unpublished data).
2.1.3 Scale of peptide synthesis—A synthetic scale of between 10 and 25 μmol for
each peptide is sufficient to yield at least 5 mg of purified peptide, even if the synthesis and/
or purification is difficult. This amount is sufficient to print hundreds of microarrays and




1. Peptide synthesizer (Symphony or PS-3 synthesizers from Protein Technologies,
Inc. or equivalent)
2. Freeze-dryer with condenser temperature < −70 °C (VirTis BTK2-XL, BTK4-ZL
or equivalent) and several 600 mL vacuum flasks
3. Explosion-proof centrifuge that can accommodate 50 mL tubes
4. 2.5 mL polypropylene syringes with frit (Torviq)
5. 50 mL polypropylene centrifuge tubes
6. Resins: Biotin-PEG NovaTag™ resin (EMD), Rink amide NovaPeg resin (EMD),
H-Rink amide ChemMatrix® resin (PCAS BioMatrix), 2-Chlorotrityl chloride resin
(EMD)
7. Standard Fmoc derivatives of the 20 coded L-amino acids: Fmoc-Ala-OH, Fmoc-
Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp (OtBu)-OH, Fmoc-Cys(Trt)-OH,
Fmoc-Gln(Trt)-OH, Fmoc-Glu (OtBu)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH,
Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Phe-
OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Trp(Boc)-OH,
Fmoc-Val-OH, Fmoc-Tyr(tBu)-OH can be purchased prepacked in vials from a
synthesizer vendor or numerous commercial suppliers.
8. Fmoc derivatives of PTM-modified amino acids and other nonstandard derivatives:
Fmoc-Asp(Mpe)-OH, Fmoc-Arg(Me,Pbf)-OH, Fmoc-Arg(Me2a,Pbf)-OH, Fmoc-
Arg(Me2s,Boc2)-OH, 1 Fmoc-Cit(Pbf)-OH, Fmoc-Lys(biotin)-OH, Fmoc-
Lys(Me,Boc)-OH, Fmoc-Lys(Me2)-OH·HCl, Fmoc-Lys(Me3Cl)-OH, Fmoc-
Ser(PHO3Bzl)-OH, Fmoc-Thr(PHO3Bzl)-OH), and coupling reagents (N,N′-
diisopropylcarbodiimide (DIC), O-(7-azabenzotriazol-1-yl)-N,N,N′, N′-
1Currently, commercially available only as a sodium salt: Fmoc-SDMA(Boc)2-ONa.
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tetramethyluronium hexafluorophosphate (HATU), and 1-hydroxy-7-
azabenzotriazole (HOAt)) can be purchased from a number of commercial vendors.
9. Solvents and reagents: N,N-dimethylformamide (DMF), N-methyl-2-pyrollidone
(NMP), dichloromethane (DCM), diethyl ether (anhydrous), piperidine, N,N-
diisopropylethylamine (DIEA), 4-methylmorpholine, trifluorocaetic acid (TFA) can
be purchased from numerous commercial suppliers.
10. A ninhydrin test kit can be purchased from AnaSpec. Note: Ninhydrin test reagents
are toxic and corrosive and must be handled with care.
All canonical Fmoc-amino acids and Fmoc-Lys(Ac)-OH were coupled using
automated Fmoc SPPS. All other modified amino acid derivatives were coupled
manually as described below.
The peptide PTMs represented in our peptide library and Fmoc derivatives used to introduce
PTMs are listed in Table 6.1 and Fig. 6.2B.
Special considerations for the introduction of modified amino acids:
1. Lys(Me2): Partial removal of the Fmoc-protecting group is observed from fully
protected Fmoc-peptide-resins containing this residue after a few hours at room
temperature. The presence of this residue, especially near the C-terminal end of the
peptide sequence, has a negative influence on the overall quality of peptide
synthesis.
2. Lys(Me3): Coupling is difficult, and in most cases, a second coupling is required.
Presence of this residue has a negative influence on the overall quality of peptide
synthesis, especially if the peptide is prone to aspartimide formation.
3. pSer and pThr: Four equivalents of base (DIEA or 4-methylmorpholine) should be
used. If used on an automated synthesizer, longer coupling times (1–2 h) or double
coupling is required.
Resin preparation: In a reaction vessel, 25–100 μmol of resin is washed with DCM and
DMF (3×10 min with each solvent) and the reaction vessel is then connected to a peptide
synthesizer. If the resin is Fmoc-protected, the Fmoc group is removed by treatment with
20% piperidine in DMF (2×15 min) and the resin is washed with DMF (5×1 min).
PEG linker incorporation (25 μmol scale): 0.1 mmol (4 equiv) of PEG linker (N-
(Fmoc-8-amino-3,6-dioxa-octyl)-succinamic acid) and HATU is mixed with 1.5 mL NMP
and 0.3 mmol DIEA. The solution is added to the Fmoc-deprotected on resin (25 μmol). The
resin is mixed for 2 h (slow nitrogen flow) and washed with DMF (3×0.5 min). If a
ninhydrin test is positive (incomplete coupling, blue color), the coupling procedure is
repeated. The Fmoc group is removed as described in the resin preparation procedure above.
D-biotin incorporation: N-terminal D-biotin (25 μmol scale) is incorporated as follows:
0.1 mmol (4 equiv) of D-biotin, HATU, and HOAt is mixed with 2 mL NMP and 0.3 mmol
DIEA. The solution is added to the Fmoc-deprotected peptide on resin (25 μmol). The resin
is gently mixed for 2 h (slow nitrogen flow) and washed with DMF (3×0.5 min). If a
ninhydrin test is positive (incomplete coupling, blue color), the coupling procedure is
repeated. Note: Histone peptides for N-terminal tag incorporation were synthesized on 2-
chlorotrityl resin (in C-terminal peptide acid form).
The C-terminal D-biotin tag (a preparation of Fmoc-Lys(biotin)-Rink amide resin, 1 mmol
scale) is incorporated as follows: 2 mmol (2 equiv) of Fmoc-Lys(biotin)-OH, DIC, and
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HOAt is mixed with 15 mL NMP and 4 mmol DIEA (if needed, more NMP is added to
dissolve reagents). The solution is added to the Fmoc-deprotected peptide on resin (25
μmol). The resin is mixed for 2 h (slow nitrogen flow) and washed with DMF (3×0.5 min).
If a ninhydrin test is positive (incomplete coupling, blue color), the coupling procedure is
repeated. The Fmoc group is removed as described in the resin preparation procedure above.
Note: For synthesis of C-terminally biotinylated peptides with PEG linker, Biotin-PEG
NovaTag™ resin is used.
Coupling/deprotection cycles
Protocol A (automated peptide synthesis): If present, the Fmoc-protecting group is first
removed by treatment with 20% piperidine in DMF (2×15 min) and the resin is washed with
DMF (3×1 min), using a synthesizer manual control mode.
A1 (PS-3 synthesizer, 25–100 μmol scale): Each synthesis cycle contains the following
steps: washing (DMF, 3×0.5 min), coupling (0.4 mmol amino acid, 0.4 mmol HATU, 1.2
mmol 4-methylmorpholine in DMF, 50 min), washing (DMF, 3×0.5 min), deprotecting
(20% piperidine in DMF, 2×7 min), and washing (DMF, 3×0.5 min).
A2 (Symphony synthesizer, 25 μmol scale): Each synthesis cycle contains the following
steps: washing (DMF, 3×0.5 min), coupling (0.125 mmol amino acid, 0.125 mmol HATU,
0.375 mmol 4-methylmorpholine in DMF, 50 min or 2×20 min for double coupling),
washing (DMF, 4×0.5 min), deprotecting (20% piperidine in DMF, 2×7 min), and washing
(DMF, 3×0.5 min).
Protocol B (manual coupling, 25 μmol synthesis scale): Fmoc-deprotected resin is washed
with DMF (4×0.5 min). 0.1 mmol (4 equiv) of PTM-modified Fmoc-amino acid, HATU,
and HOAt is mixed with 1 mL NMP and 0.3 mmol DIEA is added. If needed, additional
NMP (<1 mL) is added to obtain a clear solution (Note: use a sonic bath to speed up this
operation). This solution is added to 25 μmol resin.
After 2 h of gentle mixing (slow nitrogen flow), the resin is washed with DMF (3×0.5 min)
and a ninhydrin test is performed. If the test is positive (incomplete coupling, blue color),
the coupling procedure is repeated.
Protocol C (manual coupling, 25 μmol synthesis scale): Similar to Protocol B, but DMF is
used as a solvent and 0.4 mmol DIEA is added.
Cleavage from resin (25 μmol scale)
1. After synthesis and final Fmoc deprotection (in some cases, followed by N-
terminus acetylation or biotinylation), the resin is transferred to a 2.5-mL
polypropylene syringe with frit, washed with DMF (3×0.5 min), DCM (3×0.5 min),
and methanol (or diethyl ether for ChemMatrix resin, 2×0.5 min). The resin is then
air-dried by application of vacuum for 5 min2 and dried by lyophilization
overnight.
2. A cleavage cocktail is prepared by mixing water, EDT,3 TIS, and TFA
(2.5:2.5:1:94 volume ratio), and 1 mL is added to the resin (2 mL to ChemMatrix
resin) in a 2.5-mL syringe and gently agitated for 3 h. The mixture is filtered
2Note: Long air exposure may result in biotin tag and Met residue oxidation.
3We replaced EDT with the almost odorless 3,6-dioxa-1,8-octanedithiol (TCI America).
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directly into 20 mL cold diethyl ether in a 50-mL conical tube, and the resin is
washed 2×0.5 mL TFA. The precipitated peptide is separated by centrifugation and
washed 3×3 mL with diethyl ether by mixing, centrifugation, and decantation. The
crude peptide is air-dried for 5 min,4 dissolved in a water/acetonitrile mixture (the
sonic bath is very effective for dissolving peptides), frozen at − 80 °C, and
lyophilized.
2.3. Peptide purification, analysis, and preparation for printing
Equipment and chemicals
1. Semipreparative HPLC system with UV detector and optional fraction collector
2. C18 RP-HPLC semipreparative column (diameter: 10–22 mm, length: 150–250
mm). We tested several C18 columns, and for peptides representing histone tail
sequences, the best separations are achieved using a Waters SymmetryShield
RP-18 5 μm column (19×150 mm column).
3. Analytical RP-HPLC column
4. Acetonitrile, HPLC grade (~1 L/peptide). Note: Toxic.
5. Water, HPLC grade
6. TFA, HPLC grade. Note: Toxic and corrosive.
Purification of lyophilized peptides is carried out by RP-HPLC according to the following
protocol:
1. Lyophilized crude peptide (10–20 mg) is dissolved in 1 mL of water (if the peptide
is insoluble in water, 25–50% acetonitrile in water is used).
2. 100 μL of this solution is used for the first injection to determine general gradient
parameters. For the peptides representing histone tail sequences, the initial gradient
conditions are linear water (0.1% TFA)—acetonitrile (0.1% TFA) gradient from
5% to 30% acetonitrile over 25 min. Histone peptides derived from internal
sequences are separated using an initial gradient from 5% to 60% acetonitrile over
25 min. The subsequent injections are larger (300–500 μL injection volumes for
~20 mg/mL peptide concentration). The fractions containing peptide (usually one
major peak and 2–5 minor peaks) are collected using UV signal-guided fraction
collection (wavelength 220 nm).
3. Fractions are checked for the presence of the correct product using MALDI-TOF
MS. Fractions containing the desired peptide are combined and lyophilized.
4. The peptide purity is determined using analytical RP-HPLC.
Generally, our experience is that the use of PEG-based SPPS resins (ChemMatrix
or NovaPeg resins), HATU as a coupling reagent, and optimized protocols
(described above) warrants high success rates in the synthesis of high-quality
histone peptides. Nevertheless, impurities and byproducts are present in crude
peptides and, in some cases (especially for long sequences with multiple PTMs),
difficult to remove by preparative RP-HPLC.
The most common impurities observed on MS spectra are biotin tag oxidation (M+16 Da)
and a Rink amide MBHA resin linker “miscleavage” (M +163 Da). Similar Rink resin
“miscleavage” has been reported elsewhere (Stathopoulos, Papas, & Tsikaris, 2006). Both
4Long air exposure of resin or crude peptide may result in oxidation of Cys and Met residues and biotin.
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impurities are usually at low levels and have no negative effect on microarrays, as oxidized
biotin still binds to streptavidin, and the additional C-terminal 4-(2-amino-2-
oxoethoxy)benzyl group has no effect on peptide presentation. However, the 4-(2-amino-2-
oxoethoxy)benzyl group may affect the peptide purification and analysis process, as
peptides containing this group have strong UV absorption at 270 nm. Biotin oxidation can
be minimized by using a thiol scavenger during peptide cleavage and by minimizing peptide
air exposure. The Rink linker adducts can be avoided by using related amide resins, such as
those with Pal or Ramage linkers (PCAS BioMatrix, Inc.). Other common impurities present
are the products of incomplete couplings (sequence deletions), especially at modified amino
acid positions and the next coupled residue. After RP-HPLC purification, these by-products
are present at low levels (total impurities are usually at <10%). We have had to repeat
synthesis only for a few peptides due to incomplete couplings or side reactions. Of interest,
we experienced a severe problem with the synthesis of H3K79me3 in a peptide containing
H3 residues 74–84 due to extensive aspartimide/piperidide formation at the aspartic acid
residues in the sequence (Subirós-Funosas, El-Faham, & Albericio, 2011). We were able to
suppress aspartimide formation by using Fmoc-Asp(Mpe)-OH (EMD) to introduce Asp
residues and the addition of HOBt (0.1 M) to 20% piperidine in DMF.
Peptides storage and preparation for printing: Lyophilized peptides can be stored at −80
°C for several years without detectable deterioration. Peptides containing Met, Cys, Asp,
Asn, and Trp residues are less stable and should be reanalyzed for deterioration before usage
after more than 1 year of storage. Peptide stock solutions (1 mg/mL in water), are stable for
~12 months at −80 °C and should be periodically analyzed for deterioration. Note: Frequent
freeze/thaw cycles reduce the shelf life of peptide solutions and should be avoided.
3. MICROARRAY PRINTING
The printing of peptide microarrays is ultimately a compromise between the number of
features to be printed, the maximal number of spots of a given diameter that will fit on a
slide, the number of pins used for printing, and the time required to print. Likewise, the
ultimate quality of the data is affected by a number of factors such as the quality of the
printed spot, the variability of data that can be collected across a given slide, and the
reproducibility of printing across multiple slides. Here, we provide basic protocols to
prepare peptides for arraying. We also outline a methodology for printing and processing the
slides, and we discuss strategies to optimize a number of variables in the printing process.
3.1. Slide layout
Peptide microarrays provide a rapid, reproducible way to simultaneously assess how protein
factors interact with thousands of different peptide substrates. Unlike DNA microarrays,
which traditionally are internally controlled by hybridization in two channels (experimental
and control), it is difficult to internally control binding to peptide microarrays (Nahtman et
al., 2007). Fortunately, as the number of peptide substrates is only a small fraction of the
total number of unique features that can be printed on a slide, peptides can be spotted
numerous times and in numerous locations to build in a method of evaluating the quality of
a measurement. While we often vary the number of spots per peptide printed on a given
slide, we have three basic criteria that we use when designing a slide layout, such as the one
depicted in Fig. 6.3A. (1) All peptides should be printed by at least two different pins—to
account for variability in spotting between individual pins. (2) Each peptide should be
printed by a given pin as a grouping of at least two spots—to account for inconsistencies in
the printing of individual spots. (3) The set of peptides used should be printed in at least two
different locations on each slide following points 1 and 2 mentioned above to account for
local hybridization differences across a given slide. Using this basic set of criteria, each
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individual peptide should be printed no fewer than eight times (2×2×2=8) on every
individual slide.
3.2. Biotinylated controls
In order to better control the quality of the data collected using peptide microarrays, a
number of biotinylated control molecules are included. First, a fluorescent tracer
(biotinylated fluorescein) is added to the microarray printing buffer (see Section 3.4), which
can be used as a positive control for printing. This control allows for the distinction between
an unprinted spot and a negative binding event. Similarly, we often recombinantly express
proteins as fusions to glutathione-S-transferase (GST). Therefore, we include both
biotinylated GST and a biotinylated IgG as positive controls for antibody binding in our
hybridization assay (see Section 4). Biotinylation of protein controls is carried out using EZ-
Link® Sulfo-NHS-Biotin (Thermo/Pierce Prod. No. 20217), according to the manufacturer’s
instructions. Briefly, protein in phosphate-buffered saline (PBS), pH 7.6, was incubated with
a 20-fold molar excess of EZ-Link® Sulfo-NHS-Biotin at room temperature for 1 h.
Unreacted EZ-Link® Sulfo-NHS-Biotin was removed by extensive dialysis against PBS, pH
7.6.
3.3. Reducing sample carryover
One of the most difficult obstacles when printing peptide microarrays is cross-contamination
of samples during printing. This is particularly an issue when arraying histone peptides that,
in many cases, vary by only a single PTM. Furthermore, cationic peptides, such as histone
peptides, have been reported to nonspecifically adsorb onto surfaces such as printing pins
(Chico, Given, & Miller, 2003; Fuchs & Raines, 2005). Therefore, we employed several
strategies to be able to both identify and reduce sample carryover. First, because our histone
peptide library is made up of peptides from all four core histones, we arrange our sample
printing plate such that two peptides derived from the same tail are never printed
sequentially by one pin (Fig. 6.3A). This enables us to identify potential sample carryover,
which would manifest as a large number of unexpected positive interactions on the
microarray. Second, we observed that histone peptides become strongly adsorbed onto the
surface of stainless steel pins. Note: we use a channeled Stealth 3 pin from Arrayit for
printing. Carryover can also be decreased using a solid pin; however, channeled pins are
able to print more spots per sample dipping and, thus, greatly decrease printing time. We
find that adding an excess of bovine serum albumin (BSA) (1% w/v final concentration)
effectively reduces nonspecific binding of histone peptides. Perhaps the most successful way
to minimize sample carryover is to develop an effective washing protocol. Depending on the
arrayer, you may have access to a flowing water bath and a sonicating bath. We found
multiple rounds of alternating sonication and washing was most effective. Last, the addition
of a single porous nylon slide (such as SuperNylon from Arrayit) as the last slide printed
promotes absorption of any peptide remaining on the pin tip prior to washing.
3.4. Preparing the sample plate
Reagents
1. 384 v-bottomed microplate
2. Powdered BSA
3. Fluorescein-labeled biotin
4. 2× protein printing buffer (Arrayit)
5. Filtered distilled water (ddH2O)
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1. Prepare 100 μM stock solutions of each biotinylated histone peptide in 0.2 μm
filtered ddH2O.
2. Add 3 μL of peptide stock to an appropriate well in a 384-well plate.
3. Assemble the microarray printing buffer (1× protein printing buffer, 1% BSA w/v,
and 5 μg/mL fluorescein-labeled biotin), and add 7 μL to each well containing
peptide.
4. Cover the plate with a plate seal to prevent evaporation and store refrigerated, if
necessary, for no more than a few hours.
5. Immediately prior to printing, spin the plate in a centrifuge equipped with a
microplate adaptor at 500×g for 2 min to collect samples and remove air bubbles.
3.5. Printing protocol
Equipment and reagents
1. Arrayer (such as Omnigrid 100 from Genomic Solutions/Digilab) equipped with
HEPA air filtration
2. Vacuum source
3. Peristaltic pump with two 10 L wash reservoirs
4. Sonicating bath
5. Printing pin(s) (we used SMP6 Stealth pins from Arrayit)
6. Glass blotting pad (such as JMGR000U04)
7. Streptavidin-coated slides (such as SuperStreptavidin slides from Arrayit)
8. Nylon-coated slide (such as SuperNylon slide from Arrayit)
9. Humidifier
10. Filter paper
11. PBS, pH 7.6
Prior to printing
1. Prepare the arrayer by turning on the HEPA filtration unit and adjusting humidity,
if necessary, to between 50% and 60%. Note: The proper level of humidity is
crucial to a number of microarray printing aspects including spot morphology and
pin drying.
2. Clean pins and printhead according to the manufacturer’s instructions. Regular
cleaning of the printhead is essential to remove oxidation and prevent pin sticking.
Likewise, pins should be cleaned between every printing.
3. Insert a test pin(s) and adjust the pin depth in the sonicating, washing, and drying
stations according to the arrayer manufacturer’s instructions. Similarly, adjust the
pin depth on the microscope slide microarray, the glass blot pad (if used), and the
sample plate.
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1. Set printing parameters in the Z-direction. We used a velocity of 13.75 cm/s and
acceleration and deceleration of 256 and 128 cm/s2, respectively, for both sample
dipping and printing.
2. Set the wash program to direct pin washing between samples as follows: sonication
5 s/water wash 5 s (repeated 7×) followed by water wash 2 s/vacuum dry 2 s
(repeated 5×) followed by vacuum dry for 5 s. Careful and complete washing is
necessary to minimize carryover. Complete pin drying between samples is also
critical to assure sample can be loaded onto pins.
3. Set sample loading parameters with pins dipping into sample 2×1 s and then being
blotted 5× for 200 ms onto a glass blot pad.
4. Set pins to redip (2×1 s) into sample (without washing) once every 10–15 slides.
Printing
1. Carefully remove test pins from printhead.
2. Wipe the collars of the printing pins with a lint-free cloth and load into the
printhead. Be cautious not to touch the pin tips and minimize inadvertent contact of
the pin tip with the printhead.
3. Align blank streptavidin-coated microarray slides onto slide holders. We typically
print a series (10–15 slides—see Step 7 above) of blank, uncoated microscope
slides before the coated slides to remove any residual peptide that might have
carried over from the previous sample. The last slide printed should be a
SuperNylon slide (Arrayit), which aids in removal of excess sample prior to
washing (see above).
4. Load the sample microplate and remove the plate cover.
5. Set program to start printing. Note: Exercise extreme care when the arrayer is in
use as it is a large piece of equipment with moving parts. Observe the printing of at
least one sample to ensure there are no errors or obstructions and make sure your
equipment is accompanied with an emergency shut-off switch.
Postprinting processing
1. Typically, the printed spots will dry during the printing run. The relative success of
the printing can be assessed by breathing on the underside of one of the blank
slides, allowing the spots to appear. It is not uncommon to have occasional pin
sticks throughout the run leading to blank areas. However, these are usually
minimized by adhering to the instructions above (Steps 2, 3, and 9).
2. Place the printed slides, spots up, on a wet piece of filter paper in a humidified
environment and place at 4 °C overnight. We do this by placing wet filter paper on
large glass plates set at the bottom of a shallow cardboard box. We place a beaker
of water in the box and cover the box with plastic wrap. This serves to rehydrate
the spots, allowing greater interaction between the biotinylated peptides and the
streptavidin-coated surface.
3. Place 200 μL of a biotin-containing blocking buffer, such as Super-Streptavidin
blocking buffer (Arrayit), on each printed slide and carefully cover with a 25×60
mm coverslip. Incubate for 1 h at 4 °C to block the remaining microarray surface.
4. Wash the slides with PBS, pH 7.6, two times for 10 min each.
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5. Dry slides quickly either by placing the slide in a 50-mL conical tube and
centrifuging for 2 min at 800×g or by blowing dry with a stream of filtered air
(laboratory forced air may contain oils and autofluorescent particulate matter).
6. Printed slides can be stored at 4 °C in the dark for at least 60 days. While longer-
term storage, or storage at −20 °C or −80 °F, is theoretically possible, we have not
yet performed studies to evaluate the length of time (and subsequent quality) of
these arrays over time and after freezing.
4. ANALYSIS OF ANTIBODIES, EFFECTOR PROTEINS, AND ENZYMES
4.1. General hybridization protocol
Biotinylated histone peptide microarrays are a well-suited platform for semi-quantitative
high-throughput interrogation of the binding specificity of antibodies and effector proteins.
They have also proven useful for examining the influence that combinatorial PTMs have on
the recognition of an effector protein. Additionally, the hybridization procedure outlined
below can be modified to determine the substrate specificity of a histone-modifying enzyme
(see Section 4.5). A typical workflow for effector protein analysis is depicted in Fig. 6.3B
and detailed in the following section. All steps are performed at 4 °C with gentle rotation
unless otherwise noted. Modifications to this protocol and general considerations are
discussed in subsequent sections. Note: If necessary, the use of nitrile gloves is preferred, as
the powder from some latex gloves emits fluorescence and should therefore be avoided
when handling slide-based microarrays.
Equipment and reagents
1. Cold PBS, pH 7.6
2. Powdered BSA
3. Tween-20
4. Nontreated four-well dish (such Thermo #267061)
5. 25×60 mm coverslips
6. Plastic container with lid
7. Whatman filter paper
8. Fluorescent-labeled secondary antibody (such as Invitrogen Alexafluor647-
conjugated antirabbit (#A21244) or mouse (#A21235))
9. Microarray scanner capable of scanning at <25 μm resolution, equipped with
analysis software (such as Typhoon Trio+ equipped with ImageQuant TL—GE
Healthcare)
Procedure
1. Prepare the hybridization buffer (PBS, pH 7.6, 5% BSA w/v, 0.1% Tween-20).
2. Incubate the microarray slide with hybridization buffer in a nontreated four-well
dish for 1 h to block nonspecific binding.
3. Prepare 200 μL of a 1 μM solution of your protein of interest in hybridization
buffer.
4. Following the blocking step, place the microarray slide in a humidified chamber to
prevent the slide from drying. Several options that work well in our hands are
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sealable Tupperware with a strip of damp Whatman paper or an elevated
microscope slide incubation chamber with a well that can be filled with water.
5. Pipet drop-wise 200 μL of the protein solution directly over the region of the slide
spotted with peptides. Carefully lay a coverslip over the slide, trying to minimize
the presence of air bubbles.
6. Incubate at 4 °C overnight in the dark without rotation.
7. Remove the coverslip (should easily slide off as long as the microarray has not
dried out) and wash the slide 3× for 5 min with PBS, pH 7.6.
8. Bound protein is detected by a series of antibody incubation steps. Prepare primary
antibody dilution (specific to protein affinity tag) in hybridization buffer and
incubate on the microarray for several hours with gentle rotation. The incubation
time will vary depending on the antibody chosen, and this step may need
optimization. Generally, 2–3 h is used as a starting point. It is helpful to print
(along with the peptide library) a biotinylated primary antibody epitope or protein
(in the case of GST) on the microarray as a positive control for this step.
9. Wash the slide 3× for 5 min with PBS, pH 7.6.
10. Prepare a fluorescent secondary antibody dilution (1:5000–1:10,000 for
Alexafluor-647) in hybridization buffer and incubate slide for 30 min in the dark
with gentle rotation. To optimize and control for secondary antibody binding, spot
a biotinylated host-specific IgG on the microarray.
11. Wash the slide 3× for 5 min with PBS, pH 7.6, in the dark.
12. Dip the microarray several times in 0.1× PBS, pH 7.6, to remove excess salt.
13. Dry the slide by either filtered air or centrifugation in a 50-mL conical tube at
800×g for 2 min.
14. Proceed to the detection step. Fluorescent antibody signals may remain for 24 h or
longer. However, for best results, it is recommended to scan the microarray slide
within a few hours of incubation.
4.2. Hybridization considerations
4.2.1 Antibodies—Probing a microarray with a histone antibody is straightforward and
can typically be completed within several hours. Blocking the microarray prior to antibody
incubation is generally not necessary. The concentration of antibody hybridized to the
microarray may need optimization. A recommended starting dilution should be within the
range of detection by western blot that is empirically determined for the antibody (e.g.,
between 1:1000 and 1:50,000). The procedure described in Section 4.1 should be followed
beginning at Step 8. The use of a coverslip for incubation is optional if reagent is limiting.
4.2.2 Effector proteins—The concentration of protein hybridized to the microarray is an
important variable in the procedure detailed in Section 4.1. In our hands, a final
concentration of 1–2 μM in hybridization buffer is sufficient for detection of binding
interactions with low μM affinity. Incubation with higher concentrations of protein typically
increases background, making detection and reproducibility more challenging. While most
storage buffers are compatible with this microarray platform, it is best to dilute the protein
as much as possible into hybridization buffer prior to arraying. Barring stability issues, we
prefer to dialyze and store our proteins for arraying in PBS, pH 7.6, with up to 20% glycerol.
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The labeling approach described in Section 4.1 relies on the recognition of an effector
protein by an antibody specific to an epitope tag. We typically use either 6×-HIS or GST for
both purification and detection. These tagging methods are our preferred choice due to the
broad commercial availability of purification reagents and antibodies to recognize these
epitopes, but other tagging methods should also work as long as an antibody is designed to
recognize the native epitope. (Note: Others and we have observed that recombinantly
expressed effector domains exhibit relatively low stability (data not shown). Therefore, we
recommend arraying purified protein as soon as possible as storage at 4 °C or even at −80
°C leads to inconsistent results).
4.3. Alternative visualization techniques
The labeling approach described in Section 4.1 is advantageous due to the amplification of
signal by layering 1° and 2° antibodies. However, alternative labeling approaches that
minimize washing steps may be desired when working with low-affinity interactions or to
minimize processing time. The microarray detection limit of the procedure described in
Section 4.1 is roughly 20–30 μM. For antibodies, this is typically not an issue. However,
many effector proteins bind weakly to histone tails, and more direct labeling methods such
as the use of Alexafluor-conjugated primary antibodies or direct protein conjugation to a
fluorescent probe or quantum dot may be desirable.
4.4. Microarray detection
Detection of microarray signals is performed using a flatbed fluorescent scanner. For
simplicity, use of the Typhoon TRIO+ imager (GE Healthcare) is discussed in this section.
However, this general procedure can be adapted for any scanner with similar capabilities.
Procedure
1. Place the microarray slide face down in a microarray slide holder. We use the GE
#00-3759-30 AA. The slide holder allows for scanning of up to two microarrays
and places the microarray at a uniform height (+3 mm) above the glass for accurate
data collection. Position the slide holder in the lower left corner of the scanner. It is
not advisable to place the slide directly on the scanner glass.
2. Set the scanner acquisition mode to fluorescence and select the 526 nm and 670 nm
emission filter sets for the biotinylated fluorescein and secondary antibody,
respectively.
3. Set the focal plane to +3 mm, check the Press Sample box, and set the orientation.
4. The scanning resolution should be set at 10 μm. It takes roughly 15 min/microarray
to scan at this resolution.
4.5. Enzyme assays
In addition to scrutinizing the binding of antibodies and effector proteins, microarrays can
also be used to probe the substrate specificity of histone-modifying enzymes. Unlike the
binding of effector proteins and antibodies, which is primarily measured through indirect
fluorescence hybridization, the activity of histone-modifying enzymes such as kinases and
methyltransferases can be measured directly using radioisotopes. Kinases can be readily
assayed on the microarrays we have described here using [γ-33P] ATP by quantifying
transfer of the gamma phosphate group. The lower energy beta emissions of [γ-33P] ATP
give better resolution of the spots; thus it is preferred over [γ-32P] ATP (Ptacek et al., 2005).
After performing a kinase assay on the slide (similar to the hybridization protocol outlined
in Section 4.1, but with the addition of a radiolabeled cofactor), phosphotransfer is most
easily detected by exposing to film. The film can then be scanned and quantified. Detection
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of other enzymatic activities (such as methylation and acetylation) using these microarrays
is possible but difficult because of the combination of the relatively low concentrations of
peptide contained within each spot and the low emission energies of 3H or 14C. However,
adjusting the size of the printed spot or printing onto different microarray surfaces (such as
PVDF or nitrocellulose) can greatly increase the concentration of printed material.
5. DATA ANALYSIS
5.1. Statistical analysis and normalization
Signal intensities for each spot on a scanned microarray are determined by densitometry
using a microarray analysis program such as ImageQuant TL (GE Healthcare) and
autocorrecting for background by subtracting the local fluorescence spot edge average. We
subsequently apply several statistical measures to the raw microarray results using a
spreadsheet application such as Microsoft Excel. An initial filter is applied to remove
individual spots whose biotinylated fluorescein intensity is less than 5% of the average
intensity for all spots on the microarray. This removes peptides that were not efficiently
spotted from further analysis. Peptides are printed (and subsequently quantified) as four
independent subarrays (labeled A–H in Fig. 6.3A), which accounts for subtle differences in
intensity across the slide. If set up according to Fig. 6.3A, each subarray contains all
peptides—spotted six times each. Red channel intensities (corresponding to positive
interactions) are then normalized for all spots by dividing the intensity value by the sum of
all intensities within a subarray. The six spots for each peptide are then averaged, outliers
are removed using a Grubbs test, and this average is then treated as a single value for each
subarray. The four normalized values for each subarray (totaled from the four subarrays on
the slide) are then used to calculate a mean, standard deviation, and standard error of the
mean.
5.2. Data presentation
Presentation of peptide microarray data can take several forms, as depicted in Fig. 6.4.
Scatter plots are informative for determining reproducibility across microarrays and for
estimating the level of background signal for a given microarray. Figure 6.4A shows an XY
scatter of two independent microarray experiments with a polyclonal antibody raised to
recognize trimethylation at lysine 4 of histone H3 (H3K4) (Fig. 6.4A). Typically, the R2
value for antibodies is ≥0.9 and ≥0.8 for effector proteins (Fuchs et al., 2011). Importantly,
the large number of features spotted allows for the statistical analysis of microarray results.
Figure 6.4B depicts statistically significant differences in binding between different H3K4
methyl-containing peptides and the PHD domain of a V(D)J recombination factor, Rag2.
Likewise, data can be visualized as a heatmap to show relative differences in binding for a
larger number of peptides (Fig. 6.4C). We commonly normalize the mean calculated values
to either the most intense value across all peptides or the peptide for which a given antibody
or effector protein is known to interact, and data are plotted on a relative scale from 0 to 1 or
−1 to 1, respectively.
6. SUMMARY AND PERSPECTIVES
Peptide microarray methodologies have proven valuable for advancing our understanding of
how histone PTMs (1) coordinate the binding of effector proteins, (2) alter the substrate
specificity of histone-modifying enzymes, and (3) alter the specificity of the modification-
specific antibodies we rely so heavily on for various techniques in chromatin biology (Bock
et al., 2011; Fuchs et al., 2011; Fuchs & Strahl, 2011). The methods detailed in this chapter
should serve as comprehensive guidelines for the various aspects of histone peptide
synthesis, microarray fabrication and hybridization, and data analysis such that these
approaches are accessible to any laboratory. While various microarray approaches have
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previously been described to assess the binding interactions with histone PTMs (Bock et al.,
2011; Bua et al., 2009; Fuchs et al., 2011; Garske et al., 2010; Nady et al., 2008), we feel
our approach offers several distinct advantages. Specifically, by synthesizing peptides
individually, we have the ability to evaluate the purity of all peptides prior to printing. The
inclusion of a biotin tracer is an important control for monitoring printing efficiency, which
allows the user to filter potential false negatives that result from printing errors. Also, the
redundancy of printed peptides (four groups of six spots printed by two different pins)
allows for robust statistical analysis of binding interactions.
The ability to rapidly scrutinize the binding of proteins to thousands of peptides in a single
experiment has its clear advantages, but as with any high-throughput proteomics screening
method, there are several limitations to this technology. The generation of a high-quality
biotinylated peptide library is at the root of the success of this methodology. Histone peptide
synthesis is not trivial, even for the most experienced of peptide chemists. While many of
the potential pitfalls of peptide synthesis are described herein, the seemingly endless
variability in peptide design will inevitably pose a challenge. Furthermore, the threshold of
detection following protein hybridization is undoubtedly the limiting factor for peptide
arraying. We have difficulty detecting binding interactions with affinities weaker than 20–30
μM. For antibodies, this is not an issue. However, the dynamic interaction of effector
proteins with histone PTMs often translates to weak binding affinities. A classic example is
the binding of bromodomains to single acetyllysine residues, which is often measured with
affinities >100 μM, and has been difficult for us to characterize on the microarrays.
Currently our microarray approach can only semiquantitatively assess the binding of effector
proteins. Therefore, we feel our microarrays are suitable for determining whether a binding
interaction is strong, weak, or undetectable. Importantly, these trends are reproducible with
more quantitative biophysical approaches like ITC, surface plasmon resonance, or
fluorescence polarization.
A number of enzymes and effector proteins have been identified to prefer nucleosomal
substrates to peptides, therefore limiting the utility of peptide microarrays for these
circumstances. This is currently a limitation for all histone peptide-based approaches.
Recombinant nucleosomes carrying specific PTMs can be reconstituted in vitro, but these
processes are labor intensive and not high-throughput. However, it is conceivable that a
future high-density nucleosome array approach will also be developed to study how proteins
and protein complexes interact with these larger structures.
Similar principles of PTM recognition by effector proteins govern biology beyond the
chromatin landscape. Combinatorial PTMs have been shown to dictate the interactions of
many biologically important proteins including RNA polymerase II and p53 (Fuchs,
Laribee, & Strahl, 2009; Phatnani & Greenleaf, 2006; Sims & Reinberg, 2008). The
adaptability of this microarray methodology for the design of nonhistone posttranslationally
modified peptides is straightforward and will inevitably advance the progress toward
deciphering both histone and more general protein PTM codes.
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A representation of select posttranslational modifications (PTMs) on human histones.
Depicted are the PTMs that are most amenable for peptide synthesis, such as acetylation
(ac), methylation (me), and phosphorylation (P). *Histone lysine methylation occurs in three
forms (mono-, di-, and trimethylation), as does arginine methylation (monomethylation,
symmetric, and asymmetric dimethylation).
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Chemical derivatives used for the synthesis of modified histone tails suitable for arraying.
(A) N- and C-terminal biotin tags with PEG linkers. (B) Derivatives used for PTM
incorporation.
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Slide design and workflow for peptide arraying. (A) A suggested layout of peptides for
printing, as detailed in Chapter 3. (B) Depiction of the stepwise procedure for peptide
arraying of an effector protein from peptide immobilization to antibody hybridization and
visualization. Positive interactions are visualized as red fluorescence. All printed spots show
green fluorescence from the biotinylated fluorescein printing control.
Rothbart et al. Page 21














Typical data presentation for peptide array results. (A) Scatter plot showing the
reproducibility of two arrays probed with an H3K4me3 antibody (Millipore #07-473, Lot
#DAM1623866). Analysis of H3K4 methylation states shows no binding to H3K4me1-
containing peptides (green), weak affinity for most H3K4me2-containing peptides (blue),
and strong affinity for most H3K4me3-containing peptides (red) with the exception of
several combinatorial PTMs that perturb binding to H3K4me3. All other peptides, including
H3 peptides with no H3K4 methylation, are shown in black. (B) Array analysis of the PHD
finger of the Rag2 V(D)J recombination factor identifies specificity for H3K4me3 as
previously described (Ramon-Maiques et al., 2007). Peptide interactions were normalized to
the average intensity of H3K4me3. Intensities were compared by two-way analysis of
variance with 99% confidence intervals (**). (C) Heatmap depicting the effects of
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combinatorial PTMs on the binding of the Rag2 PHD finger to H3K4me3-containing
peptides. Binding intensities are represented relative to H3K4me3 (0, white). Enhanced (1,
red) and occluded (−1, blue) interactions are depicted. The heatmap was generated using
JavaTreeView (Saldanha, 2004).
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Table 6.1
PTM derivatives and coupling methods for histone peptide synthesis
Modified amino acid Fmoc-protected derivative Coupling method
Lys(Ac) Fmoc-Lys(Ac)-OH Standard (protocol A2 with double coupling)
Lys(Me) Fmoc-Lys(Me,Boc)-OH Manual (protocol B)
Lys(Me2) Fmoc-Lys(Me2)-OH·HCl Manual (protocol B)a
Lys(Me3) Fmoc-Lys(Me3Cl)-OH Manual (protocol B)a
Arg(Me) Fmoc-Arg(Me,Pbf)-OH Manual (protocol B)
Arg(Me2a)b Fmoc-Arg(Me2a,Pbf)-OH (Fmoc-ADMA(Pbf)-OH) Manual (protocol B)
Arg(Me2s)b Fmoc-Arg(Me2s,Boc2)-OH (Fmoc-SDMA(Boc)2-OH) Manual (protocol B)
Citc Fmoc-Cit(Pbf)-OH Standard (protocol A1 or A2)
pSer Fmoc-Ser(PHO3Bzl)-OH Manual (protocol C)a
pThr Fmoc-Thr(PHO3Bzl)-OH Manual (protocol C)a
a
See special considerations in Section 2.2.
b
Use of orthogonally protected forms of mono- and dimethyl arginine is crucial for the success of synthesis of peptides containing methylated Arg
residues. All derivatives in this table are commercially available as is, with the exception of the free acid form of the symmetric dimethyl arginine
derivative, which has been replaced with a sodium salt due to stability problems.
c
Cit refers to L-citrulline.
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